Bradley S. Stolshek, PharmD

home / authors / bradley-s-stolshek-pharmd

Articles

August 13th 2020

Psoriatic Arthritis Treatment Patterns and Costs Among Pharmacologic Treatment–Naïve Patients

Ervant J. Maksabedian Hernandez, PhD Joseph Tkacz, MS Lorena Lopez-Gonzalez, PhD, MA Kate Higgins, MPH Alexis Ogdie, MD, MSCE Bradley S. Stolshek, PharmD

We present results of an analysis of IBM MarketScan databases that evaluates treatment patterns and health care costs for treatment-naïve patients with psoriatic arthritis.

July 12th 2018

Cost of Biologic Treatment Persistence or Switching in Rheumatoid Arthritis

Tao Gu, PhD Alex Mutebi, PhD Bradley S. Stolshek, PharmD Hiangkiat Tan, MS, BSPharm

Patients with rheumatoid arthritis who switched biologics incurred higher costs than patients who persisted on biologics. Etanercept appeared to be associated with the lowest costs.

July 12th 2018

Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis

Bradley S. Stolshek, PharmD Sally W. Wade, MPH Alex Mutebi, PhD, MSc Ajita P. De, MA, MPhil, MS Rolin L. Wade, MS Jason Yeaw, MPH

Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.

July 11th 2018

Disease-Modifying Antirheumatic Drug Initiation Among Patients Newly Diagnosed With Rheumatoid Arthritis

Machaon Bonafede, PhD, MPH Barbara H. Johnson, MBA Neel Shah, PhD, BPharm David J. Harrison, PhD Derek Tang, PhD, BSPharm Bradley S. Stolshek, PharmD

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year.